Literature DB >> 33562601

FNDC5/Irisin System in Neuroinflammation and Neurodegenerative Diseases: Update and Novel Perspective.

Patrizia Pignataro1,2, Manuela Dicarlo1, Roberta Zerlotin2, Chiara Zecca3, Maria Teresa Dell'Abate3, Cinzia Buccoliero2, Giancarlo Logroscino1,3, Silvia Colucci1, Maria Grano2.   

Abstract

Irisin, the circulating peptide originating from fibronectin type III domain-containing protein 5 (FNDC5), is mainly expressed by muscle fibers under peroxisome proliferator-activated receptor gamma coactivator 1-alpha PGC1α control during exercise. In addition to several beneficial effects on health, physical activity positively affects nervous system functioning, particularly the hippocampus, resulting in amelioration of cognition impairments. Recently, FNDC5/irisin detection in hippocampal neurons and the presence of irisin in the cerebrospinal fluid opened a new intriguing chapter in irisin history. Interestingly, in the hippocampus of mice, exercise increases FNDC5 levels and upregulates brain-derived neurotrophic factor (BDNF) expression. BDNF, displaying neuroprotection and anti-inflammatory effects, is mainly produced by microglia and astrocytes. In this review, we discuss how these glial cells can morphologically and functionally switch during neuroinflammation by modulating the expression of a plethora of neuroprotective or neurotoxic factors. We also focus on studies investigating the irisin role in neurodegenerative diseases (ND). The emerging involvement of irisin as a mediator of the multiple positive effects of exercise on the brain needs further studies to better deepen this issue and the potential use in therapeutic approaches for neuroinflammation and ND.

Entities:  

Keywords:  FNDC5; irisin; neurodegeneration; neuroinflammation

Year:  2021        PMID: 33562601      PMCID: PMC7915567          DOI: 10.3390/ijms22041605

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  96 in total

1.  Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry.

Authors:  Mark P Jedrychowski; Christiane D Wrann; Joao A Paulo; Kaitlyn K Gerber; John Szpyt; Matthew M Robinson; K Sreekumaran Nair; Steven P Gygi; Bruce M Spiegelman
Journal:  Cell Metab       Date:  2015-08-13       Impact factor: 27.287

Review 2.  Microglia and Astrocytes in Disease: Dynamic Duo or Partners in Crime?

Authors:  Shane A Liddelow; Samuel E Marsh; Beth Stevens
Journal:  Trends Immunol       Date:  2020-08-17       Impact factor: 16.687

Review 3.  Microglia emerge as central players in brain disease.

Authors:  Michael W Salter; Beth Stevens
Journal:  Nat Med       Date:  2017-09-08       Impact factor: 53.440

4.  Irisin-immunoreactivity in neural and non-neural cells of the rodent.

Authors:  S L Dun; R-M Lyu; Y-H Chen; J-K Chang; J J Luo; N J Dun
Journal:  Neuroscience       Date:  2013-03-05       Impact factor: 3.590

5.  Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines.

Authors:  Hyun-Seuk Moon; Fadime Dincer; Christos S Mantzoros
Journal:  Metabolism       Date:  2013-05-07       Impact factor: 8.694

6.  Irisin protects against neuronal injury induced by oxygen-glucose deprivation in part depends on the inhibition of ROS-NLRP3 inflammatory signaling pathway.

Authors:  Juan Peng; Xian Deng; Wei Huang; Ji-Hua Yu; Jian-Xiong Wang; Jie-Ping Wang; Shi-Bin Yang; Xi Liu; Li Wang; Yun Zhang; Xiang-Yu Zhou; Hui Yang; Yan-Zheng He; Fang-Yuan Xu
Journal:  Mol Immunol       Date:  2017-09-30       Impact factor: 4.407

Review 7.  Interleukin-6 and chronic inflammation.

Authors:  Cem Gabay
Journal:  Arthritis Res Ther       Date:  2006-07-28       Impact factor: 5.156

Review 8.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

9.  Irisin Correlates Positively With BMD in a Cohort of Older Adult Patients and Downregulates the Senescent Marker p21 in Osteoblasts.

Authors:  Graziana Colaianni; Mariella Errede; Lorenzo Sanesi; Angela Notarnicola; Monica Celi; Roberta Zerlotin; Giuseppina Storlino; Patrizia Pignataro; Angela Oranger; Vito Pesce; Umberto Tarantino; Biagio Moretti; Maria Grano
Journal:  J Bone Miner Res       Date:  2020-10-29       Impact factor: 6.741

10.  Fibronectin type III domain-containing protein 5 interacts with APP and decreases amyloid β production in Alzheimer's disease.

Authors:  Yasuha Noda; Akira Kuzuya; Kyousuke Tanigawa; Mitsugu Araki; Ryoko Kawai; Biao Ma; Yoko Sasakura; Masato Maesako; Yoshitaka Tashiro; Masakazu Miyamoto; Kengo Uemura; Yasushi Okuno; Ayae Kinoshita
Journal:  Mol Brain       Date:  2018-10-24       Impact factor: 4.041

View more
  12 in total

Review 1.  Modulation of Inflammatory Mediators and Microglial Activation Through Physical Exercise in Alzheimer's and Parkinson's Diseases.

Authors:  Erin John Rieger de Almeida; Hélio Jungkenn Ibrahim; Maria Rosa Chitolina Schetinger; Cinthia Melazzo de Andrade; Andréia Machado Cardoso
Journal:  Neurochem Res       Date:  2022-08-13       Impact factor: 4.414

2.  Irisin Attenuates Pathological Neovascularization in Oxygen-Induced Retinopathy Mice.

Authors:  Jieqiong Zhang; Zhifei Liu; Haoqian Wu; Xi Chen; Qiumei Hu; Xue Li; Linlin Luo; Shiyang Ye; Jian Ye
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

3.  Irisin Serum Levels and Skeletal Muscle Assessment in a Cohort of Charcot-Marie-Tooth Patients.

Authors:  Graziana Colaianni; Angela Oranger; Manuela Dicarlo; Roberto Lovero; Giuseppina Storlino; Patrizia Pignataro; Antonietta Fontana; Francesca Di Serio; Angelica Ingravallo; Giuseppe Caputo; Alfredo Di Leo; Michele Barone; Maria Grano
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

4.  Irisin protects female mice with LPS-induced endometritis through the AMPK/NF-κB pathway.

Authors:  Xi Jiang; Ying Hu; Yingjie Zhou; Jin Chen; Chonglu Sun; Ziwei Chen; Changfeng Jing; Lexing Xu; Fuhe Liu; Wenjuan Ni; Xuefeng Yu; Lei Chen
Journal:  Iran J Basic Med Sci       Date:  2021-09       Impact factor: 2.699

Review 5.  FNDC5/Irisin: Physiology and Pathophysiology.

Authors:  Rashid Waseem; Anas Shamsi; Taj Mohammad; Md Imtaiyaz Hassan; Syed Naqui Kazim; Anis Ahmad Chaudhary; Hassan Ahmed Rudayni; Mohammed Al-Zharani; Faizan Ahmad; Asimul Islam
Journal:  Molecules       Date:  2022-02-08       Impact factor: 4.411

6.  FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells.

Authors:  Huayuan Liu; Lei Zhao; Mengya Wang; Kexin Yang; Zhipeng Jin; Chengjian Zhao; Guangjun Shi
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

7.  Irisin Ameliorates Intervertebral Disc Degeneration by Activating LATS/YAP/CTGF Signaling.

Authors:  Taiqiu Chen; Youxi Lin; Zizhao Wu; Huihong Shi; Wenjun Hu; Shaoguang Li; Yichen Que; Jincheng Qiu; Pengfei Li; Xianjian Qiu; Tongzhou Liang; Xudong Wang; Bo Gao; Hang Zhou; Zhihuai Deng; Yanbo Chen; Yuanxin Zhu; Yan Peng; Anjing Liang; Wenjie Gao; Dongsheng Huang
Journal:  Oxid Med Cell Longev       Date:  2022-07-20       Impact factor: 7.310

8.  Antidepressant Effect of Intermittent Long-Term Systemic Administration of Irisin in Mice.

Authors:  Patrizia Pignataro; Manuela Dicarlo; Roberta Zerlotin; Giuseppina Storlino; Angela Oranger; Lorenzo Sanesi; Roberto Lovero; Cinzia Buccoliero; Giorgio Mori; Graziana Colaianni; Silvia Colucci; Maria Grano
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

Review 9.  Regulation of microglia phagocytosis and potential involvement of exercise.

Authors:  Congqin Li; Yong Wang; Ying Xing; Jing Han; Yuqian Zhang; Anjing Zhang; Jian Hu; Yan Hua; Yulong Bai
Journal:  Front Cell Neurosci       Date:  2022-07-25       Impact factor: 6.147

Review 10.  Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimer's Disease Patients.

Authors:  Samo Ribarič
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.